Results 51 to 60 of about 15,404 (212)

Sitagliptin Is More Effective Than Gliclazide in Preventing  Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease

Molecules, 2022
A diet-induced non-alcoholic fatty liver disease (NAFLD) model causing obesity in rodents was used to examine whether sitagliptin and gliclazide therapies have similar protective effects on pathological liver change.
Jing Ren, Xiaoyu Wang, Christine Yee, Mark D. Gorrell, Susan V. McLennan, Stephen M. Twigg   +5 more
doaj   +1 more source

Nickel Foam Electrodes—A Versatile, Powerful, and Readily Available Tool in Electro‐Organic Synthesis

The Chemical Record, EarlyView.
Nickel foam—one material, two faces, and several versatile roles depending on electrolytic conditions. For more than 50 years, nickel foam electrodes have served in electrosynthesis as powerful and readily available electrode materials. Due to their inexpensive nature and easy handling, they have been widely employed.
Rok Narobe, Johannes Schneider, Siegfried R. Waldvogel   +2 more
wiley   +1 more source

Evaluation of Anticancer Activity of Sitagliptin against Hepatocellular Carcinoma: An In Vitro Study

Medical Journal of Babylon
Background: Hepatocellular carcinoma is a malignant liver tumor constituting greater than 90% of liver primary tumors. Most of chemotherapeutic drugs used nowadays are cytotoxic, which rise the necessity to find newer agents with anticancer activity and ...
Ruqaya A. Ameen, Ahsan F. Bairam, Haider F. Al-Zubaidy   +2 more
doaj   +1 more source

Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale, Mark Taylor, Markku Lähteenvuo, Ellenor Mittendorfer‐Rutz, Antti Tanskanen, Jari Tiihonen   +5 more
wiley   +1 more source

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

Andrology, EarlyView.
ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin, Xuefeng Ding, Xin Dang, Qingyuan Zhan   +3 more
wiley   +1 more source

Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells: A randomised, double-blind placebo-controlled feasibility trial

EBioMedicine, 2020
Background: Recurrent pregnancy loss (RPL) is associated with the loss of endometrial mesenchymal stem-like progenitor cells (eMSC). DPP4 inhibitors may increase homing and engraftment of bone marrow-derived cells to sites of tissue injury.
Shreeya Tewary, Emma S. Lucas, Risa Fujihara, Peter K. Kimani, Angela Polanco, Paul J. Brighton, Joanne Muter, Katherine J. Fishwick, Maria José Minhoto Diniz Da Costa, Lauren J. Ewington, Lauren Lacey, Satoru Takeda, Jan J. Brosens, Siobhan Quenby   +13 more
doaj   +1 more source

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

British Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

Impact of Sitagliptin on Inflammatory Biomarkers in Type 2 Diabetes Mellitus [PDF]

Background: Type 2 diabetes mellitus (T2DM) is associated with low-grade inflammatory response, which was reported to contribute to insulin resistance. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is widely used for glycemic control and has ...
Aqeel Meer AL-ZAMILY
core   +1 more source

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

BMC Endocrine Disorders, 2010
Background In a previous pooled analysis of 12 double-blind clinical studies that included data on 6,139 patients with type 2 diabetes, treatment with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was shown to be generally well tolerated ...
Guo Hua, Golm Gregory T, Johnson Jeremy, Round Elizabeth, Engel Samuel S, Williams-Herman Debora, Musser Bret J, Davies Michael J, Kaufman Keith D, Goldstein Barry J   +9 more
doaj   +1 more source

Dual Glucagon and GLP‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This post hoc analysis evaluated the effect of survodutide on beta‐cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations. Materials and Methods Trial 1404‐0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
Elif I. Ekinci, Sandra González Maldonado, Anna Unseld, Jorge Arrubla Martinez, Anita M. Hennige, Corinna Schoelch   +5 more
wiley   +1 more source